The O +
causal O +
agents O +
of O +
destructive O +
periodontal B-Disease +
disease I-Disease +
are O +
several O +
gram O -
- O -
negative O +
bacteria O -
. O +

The O +
mere O +
presence O -
, O +
however O -
, O +
in O +
the O +
dental O +
biofilm O +
does O +
not O +
guarantee O +
onset O +
of O +
the O +
disease O -
. O +

The O +
immunological O +
and O +
inflammatory O +
host O +
response O +
as O +
well O +
as O +
connective O +
tissue O +
and O +
bone O +
metabolism O +
are O +
strongly O +
influenced O +
by O +
genetic O -
, O +
acquired O +
and O +
behavioural O +
risk O +
factors O -
. O +

Among O +
the O +
last O -
, O +
tobacco O +
consumption O +
holds O +
a O +
primary O +
position O -
. O +

Prevalence O -
, O +
extent O +
and O +
severity O +
of O +
periodontitis B-Disease +
as O +
well O +
as O +
tooth B-Disease +
loss I-Disease +
and O +
edentulism B-Disease +
are O +
influenced O +
by O +
tobacco O +
consumption O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

About O +
50 O -
% O +
of O +
periodontal B-Disease +
disease I-Disease +
in O +
young O +
adults O +
is O +
attributable O +
to O +
cigarette O +
smoking O -
. O +

Postoperative O +
results O +
in O +
periodontally O +
diseased O +
smokers O +
are O +
considerably O +
poorer O +
than O +
those O +
achieved O +
in O +
non O -
- O -
smokers O -
. O +

As O +
a O +
consequence O +
smoking O +
cessation O +
has O +
to O +
be O +
in O +
corporated O +
in O +
traditional O +
treatment O +
concepts O +
for O +
inflammatory B-Disease +
periodontal I-Disease +
disease I-Disease -
. O +

Cumulative O +
evidence O +
suggests O +
a O +
possible O +
interaction O +
of O +
cooking O +
methods O +
with O +
diet O +
in O +
the O +
pathogenesis O +
of O +
breast B-Disease +
cancer I-Disease -
. O +

Studies O -
, O +
however O -
, O +
are O +
few O +
and O +
inconsistent O -
. O +

We O +
evaluated O +
the O +
association O +
of O +
animal O +
food O +
intake O +
and O +
degree O +
of O +
browning O +
by O +
deep O -
- O -
frying O +
with O +
breast B-Disease +
cancer I-Disease +
risk O +
in O +
a O +
population O -
- O -
based O +
case O -
- O -
control O +
study O +
conducted O +
during O +
1996 O -
- O -
1998 O +
among O +
Chinese O +
women O +
in O +
Shanghai O -
, O +
a O +
population O +
with O +
a O +
traditionally O +
low O +
risk O +
of O +
breast B-Disease +
cancer I-Disease -
. O +

Included O +
in O +
the O +
study O +
were O +
1459 O +
cases O +
and O +
1556 O +
age O -
- O -
frequency O -
- O -
matched O +
controls O +
with O +
response O +
rates O +
of O +
91.1 O +
and O +
90.3 O -
% O -
, O +
respectively O -
. O +

A O +
validated O +
food O +
frequency O +
questionnaire O +
was O +
used O +
to O +
obtain O +
information O +
on O +
usual O +
intake O +
of O +
animal O +
foods O +
and O +
cooking O +
oils O +
and O +
usual O +
cooking O +
methods O -
. O +

Increasing O +
intake O +
of O +
red O +
meat O +
and O +
freshwater O +
fish O +
was O +
related O +
to O +
a O +
moderately O +
elevated O +
risk O +
of O +
breast B-Disease +
cancer I-Disease +
risk O -
. O +

Stratified O +
analyses O +
showed O +
that O +
the O +
positive O +
association O +
with O +
red O +
meat O +
intake O +
was O +
primarily O +
restricted O +
to O +
those O +
who O +
used O +
deep O -
- O -
frying O +
cooking O +
method O -
, O +
particularly O +
among O +
those O +
who O +
deep O -
- O -
fried O +
foods O +
to O +
well O -
- O -
done O +
( O -
odds O +
ratio O -
, O +
1.92 O -
; O +
95 O -
% O +
confidence O +
interval O -
, O +
1.30 O -
- O -
2.83 O +
for O +
the O +
highest O +
versus O +
the O +
lowest O +
quintile O -
; O +
P O +
for O +
trend O -
, O +
0.002 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
high O +
intake O +
of O +
nonhydrogenated O +
soybean O +
cooking O +
oil O +
was O +
related O +
to O +
a O +
reduced O +
risk O +
of O +
breast B-Disease +
cancer I-Disease +
among O +
women O +
who O +
never O +
deep O -
- O -
fried O +
animal O +
foods O +
( O -
odds O +
ratio O -
, O +
0.48 O -
; O +
95 O -
% O +
confidence O +
interval O -
, O +
0.28 O -
- O -
0.82 O +
for O +
the O +
highest O +
versus O +
the O +
lowest O +
quintile O -
; O +
P O +
for O +
trend O -
, O +
0.02 O -
) O -
. O +

The O +
positive O +
association O +
of O +
breast B-Disease +
cancer I-Disease +
risk O +
with O +
red O +
meat O +
intake O -
, O +
especially O +
well O -
- O -
done O +
red O +
meat O -
, O +
was O +
more O +
pronounced O +
among O +
women O +
with O +
a O +
high O +
body O +
mass O +
index O +
than O +
those O +
without O +
this O +
risk O +
factor O -
, O +
and O +
the O +
test O +
for O +
multiplicative O +
interaction O +
was O +
statistically O +
significant O -
. O +

This O +
study O +
suggests O +
that O +
high O +
intake O +
of O +
deep O -
- O -
fried O -
, O +
well O -
- O -
done O +
red O +
meat O +
may O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
breast B-Disease +
cancer I-Disease -
, O +
and O +
the O +
positive O +
association O +
may O +
be O +
modified O +
by O +
body O +
weight O -
. O +

This O +
study O +
also O +
suggests O +
that O +
nonhydrogenated O +
soybean O +
oil O -
, O +
if O +
not O +
used O +
in O +
high O -
- O -
temperature O +
cooking O -
, O +
may O +
be O +
associated O +
with O +
a O +
reduced O +
risk O +
of O +
breast B-Disease +
cancer I-Disease -
. O +

OBJECTIVE O -
: O +
To O +
study O +
the O +
therapeutic O +
effect O +
of O +
Lespedeza O +
Michx O +
in O +
experimental O +
rat O +
model O +
of O +
minimal B-Disease +
change I-Disease +
nephropathy I-Disease +
( O -
MCN B-Disease -
) O -
. O +

METHOD O -
: O +
The O +
rat O +
MCN O +
model O +
was O +
reproduced O +
by O +
tail O -
- O -
intravenous O +
injection O +
of O +
Adriamycin O -
. O +

The O +
treatment O +
effect O +
of O +
Lespedeza O +
Michx O +
was O +
determined O +
by O +
the O +
detection O +
of O +
urine O +
protein O +
collection O +
for O +
24 O +
hours O -
, O +
malondialdehyde O +
( O -
MDA O -
) O -
, O +
superoxide O +
dismutase O +
( O -
SOD O -
) O -
, O +
ATCO O -
, O +
IL-8 O -
, O +
TNF O -
- O -
alpha O +
in O +
serum O -
, O +
and O +
renal O +
histopathological O +
changes O +
were O +
observed O +
by O +
microscope O -
. O +

RESULT O -
: O +
Lespedeza O +
Michx O +
could O +
decrease O +
the O +
contents O +
of O +
urine B-Disease +
proteinuria I-Disease -
, O +
MDA O -
, O +
IL-8 O -
, O +
and O +
TNF O -
- O -
alpha O +
in O +
serum O -
, O +
increase O +
SOD O +
level O +
and O +
improved O +
the O +
pathological O +
change O +
of O +
glomeruli O -
. O +

CONCLUSION O -
: O +
Lespedeza O +
Michx O +
was O +
effective O +
on O +
MCN O -
. O +

THE O +
AIM O +
OF O +
THIS O +
STUDY O -
: O +
was O +
to O +
assess O +
the O +
anti O -
- O -
inflammatory O +
and O +
mechanism O +
of O +
action O +
of O +
Allanblackia O +
monticola O +
( O -
Guttiferae O -
) O -
. O +

The O +
anti O -
- O -
inflammatory O +
activity O +
" O -
in O +
vivo O -
" O +
of O +
the O +
methylene O +
chloride O -
/ O -
methanol O +
extract O -
, O +
methanol O +
and O +
methylene O +
chloride O +
fractions O +
of O +
stem O +
barks O +
of O +
Allanblackia O +
monticola O -
, O +
administered O +
orally O +
at O +
doses O +
of O +
37.5 O -
; O +
75 O -
; O +
150 O +
and O +
300 O +
mg O -
/ O -
kg O -
, O +
was O +
evaluated O +
on O +
carrageenan O -
- O -
induced O +
oedema B-Disease +
in O +
rats O +
to O +
determine O +
the O +
most O +
active O +
fraction O -
. O +

Indomethacin O -
, O +
inhibitor O +
of O +
cyclo O -
- O -
oxygenase O +
was O +
used O +
as O +
reference O +
drug O -
. O +

The O +
effects O +
of O +
the O +
most O +
active O +
fraction O +
were O +
then O +
examined O +
on O +
the O +
rat O +
paw O +
oedema B-Disease +
caused O +
by O +
histamine O -
, O +
serotonin O -
, O +
arachidonic O +
acid O +
and O +
dextran O +
followed O +
by O +
its O +
ulcerogenic O +
effect O -
. O +

The O +
results O +
showed O +
that O +
the O +
methylene O +
chloride O +
fraction O +
of O +
Allanblackia O +
monticola O +
was O +
more O +
effective O +
on O +
the O +
oedema B-Disease +
caused O +
by O +
the O +
carrageenan O -
. O +

The O +
anti O -
- O -
nociceptive O +
activity O +
of O +
the O +
methylene O +
chloride O +
fraction O +
was O +
assessed O +
using O +
the O +
acetic O +
acid O -
- O -
induced O +
abdominal O +
constriction O +
model O -
, O +
formalin O +
test O +
and O +
hot O +
plate O +
test O -
. O +

At O +
150 O +
mg O -
/ O -
kg O -
, O +
Allanblackia O +
monticola O +
caused O +
maximum O +
inhibitions O +
of O +
inflammation O +
induced O +
by O +
carrageenan O +
( O -
83.33 O -
% O -
) O -
, O +
by O +
histamine O +
( O -
42.10 O -
% O -
) O -
, O +
by O +
dextran O +
( O -
40.29 O -
% O -
) O +
and O +
by O +
arachidonic O +
acid O +
( O -
64.28 O -
% O -
) O -
. O +

Allanblackia O +
monticola O +
( O -
75 O -
- O -
300 O +
mg O -
/ O -
kg O -
) O +
did O +
not O +
cause O +
significant O +
modification O +
of O +
the O +
oedema B-Disease +
induced O +
by O +
serotonin O -
. O +

Concerning O +
the O +
anti O -
- O -
nociceptive O +
properties O +
of O +
the O +
plant O -
, O +
the O +
methylene O +
chloride O +
fraction O +
( O -
75 O -
- O -
300 O +
mg O -
/ O -
kg O -
) O +
caused O +
a O +
dose O -
- O -
dependent O +
inhibition O +
on O +
abdominal O +
contractions O +
induced O +
by O +
acetic O +
acid O +
( O -
32.34 O -
- O -
77.37 O -
% O -
) O +
and O +
significantly O +
inhibited O +
the O +
inflammatory O +
pain O +
caused O +
by O +
formalin O +
( O -
40.71 O -
- O -
64.78 O -
% O -
) O -
. O +

Allanblackia O +
monticola O +
did O +
not O +
increase O +
the O +
latency O +
time O +
in O +
the O +
hot O +
plate O +
test O -
. O +

Like O +
indomethacin O +
( O -
10mg O -
/ O -
kg O -
) O -
, O +
the O +
fraction O +
at O +
the O +
dose O +
of O +
150 O +
mg O -
/ O -
kg O +
caused O +
ulceration O +
of O +
the O +
gastric O +
mucous O +
membrane O +
in O +
treated O +
rats O -
. O +

These O +
results O +
show O +
that O +
Allanblackia O +
monticola O +
has O +
an O +
anti O -
- O -
inflammatory O +
and O +
analgesic O +
activities O +
with O +
gastric O +
ulcerative O +
side O +
effects O -
. O +

Lonicera O +
caerulea O +
is O +
a O +
species O +
of O +
bush O +
native O +
to O +
the O +
Kamchatka O +
Peninsula O +
( O -
Russian O +
Far O +
East O -
) O +
whose O +
berries O +
have O +
been O +
extensively O +
studied O +
due O +
to O +
their O +
potential O +
high O +
antioxidant O +
activity O -
. O +

The O +
aim O +
of O +
our O +
work O +
was O +
to O +
investigate O +
the O +
in O +
vivo O +
effects O +
of O +
the O +
antioxidant O +
action O +
of O +
Lonicera O +
caerulea O +
berry O +
extracts O +
on O +
the O +
dynamics O +
of O +
experimentally O -
- O -
induced O +
tumors B-Disease -
. O +

Our O +
data O +
showed O +
that O +
aqueous O +
Lonicera O +
caerulaea O +
extracts O +
reduced O +
the O +
tumor B-Disease +
volume O +
when O +
administered O +
continuously O +
during O +
the O +
tumor B-Disease +
growth O +
and O +
development O +
stages O -
, O +
but O +
augmented O +
the O +
tumor B-Disease +
growth O +
when O +
the O +
administration O +
of O +
extracts O +
started O +
three O +
weeks O +
before O +
tumor B-Disease +
grafting O -
. O +

Prolonged O +
administration O +
of O +
Lonicera O +
caerulaea O +
berry O +
extracts O +
induced O +
the O +
antioxidant O +
defense O +
mechanism O +
in O +
the O +
tumor B-Disease +
tissues O -
, O +
while O +
surprisingly O +
amplifying O +
the O +
peripheral O +
oxidative O +
stress O -
. O +

Atrial B-Disease +
tachyarrhythmias I-Disease +
are O +
a O +
common O +
manifestation O +
of O +
digitalis O +
toxicity O -
. O +

Such O +
arrhythmias O +
could O +
be O +
due O +
to O +
enhanced O +
automaticity O +
of O +
subsidiary B-Disease +
atrial I-Disease +
pacemakers I-Disease +
( O -
SAP B-Disease -
) O +
compared O +
to O +
the O +
sinoatrial O +
( O -
SA O -
) O +
node O -
. O +

Halothane O +
is O +
known O +
to O +
oppose O +
digitalis O -
- O -
induced O +
ventricular B-Disease +
arrhythmias I-Disease -
. O +

Its O +
effect O +
on O +
digitalis O -
- O -
caused O +
atrial B-Disease +
arrhythmias I-Disease +
is O +
unknown O -
. O +

Therefore O -
, O +
we O +
tested O +
two O +
hypotheses O -
, O +
as O +
follows O -
. O +

First O -
, O +
increasing O +
ouabain O +
concentrations O +
would O +
enhance O +
automaticity O +
of O +
SAP B-Disease +
compared O +
to O +
the O +
SA O +
node O +
and O +
that O +
such O +
enhanced O +
automaticity O +
could O +
explain O +
digitalis O -
- O -
caused O +
atrial B-Disease +
tachyarrhythmias I-Disease -
. O +

Second O -
, O +
halothane O +
would O +
oppose O +
such O +
enhanced O +
automaticity O +
of O +
SAP B-Disease -
, O +
thereby O +
opposing O +
digitalis O -
- O -
caused O +
atrial B-Disease +
tachyarrhythmias I-Disease -
. O +

A O +
canine O +
right O +
atrial O +
preparation O +
was O +
perfused O +
via O +
the O +
SA O +
node O +
artery O +
with O +
Krebs O -
' O +
solution O +
( O -
36.0 O +
+ O -
/- O +

0.5 O +
degrees O +
C O -
) O +
equilibrated O +
with O +
97 O -
% O +
oxygen-3 O -
% O +
carbon O +
dioxide O -
. O +

Four O +
bipolar O +
extracellular O +
electrodes O +
recorded O +
the O +
site O +
of O +
earliest O +
activation O +
( O -
SEA O -
) O -
, O +
which O +
in O +
this O +
preparation O +
could O +
be O +
the O +
SA O +
node O +
or O +
increasingly O +
remote O +
sites O +
of O +
SAP B-Disease +
approximately O +
1 O -
, O +
2 O -
, O +
and O +
3 O +
cm O +
distal O +
to O +
the O +
SA O +
node O +
along O +
the O +
sulcus O +
terminalis O -
. O +

Pacemaker O +
shifts O +
to O +
SAP B-Disease +
during O +
exposure O +
to O +
drugs O +
were O +
scored O +
for O +
magnitude O +
of O +
shift O +
as O +
1 O -
, O +
2 O -
, O +
or O +
3 O +
depending O +
on O +
which O +
SAP B-Disease +
site O +
was O +
the O +
SEA O -
. O +

Magnitude O +
scores O +
were O +
summed O +
for O +
each O +
test O +
condition O +
and O +
normalized O +
by O +
dividing O +
the O +
total O +
number O +
of O +
preparations O +
tested O -
. O +

Preparations O +
( O -
n O +
= O +
48 O -
) O +
were O +
exposed O +
to O +
1 O +
or O +
2 O -
% O +
halothane O +
( O -
perfusate O +
concentrations O +
of O +
0.51 O +
+ O -
/- O +

0.01 O +
or O +
0.79 O +
+ O -
/- O +

0.03 O +
mM O -
, O +
respectively O -
) O +
and/or O +
to O +
low- O +
or O +
mid O -
- O -
therapeutic O +
( O -
2.5 O +
or O +
5 O +
x O +
10 O -
( O -
-8 O -
) O +
M O -
) O +
or O +
borderline O +
toxic O +
ouabain O +
( O -
1 O +
x O +
10 O -
( O -
-7 O -
) O +
M O -
) O -
. O +

Normalized O +
magnitude O +
scores O +
were O +
not O +
significantly O +
different O +
from O +
zero O +
( O -
control O +
value O -
) O +
with O +
any O +
halothane O +
or O +
ouabain O +
concentration O +
alone. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Olive O +
oil O +
consumption O +
is O +
protective O +
against O +
risk O +
factors O +
for O +
cardiovascular O +
and O +
cancer B-Disease +
diseases I-Disease -
. O +

A O +
nutrigenomic O +
approach O +
was O +
performed O +
to O +
assess O +
whether O +
changes O +
in O +
gene O +
expression O +
could O +
occur O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
after O +
oli O +
ve O +
oil O +
ingestion O +
at O +
postprandial O +
state O -
. O +

Six O +
healthy O +
male O +
volunteers O +
ingested O -
, O +
at O +
fasting O +
state O -
, O +
50 O +
ml O +
of O +
olive O +
oil O -
. O +

Prior O +
to O +
intervention O +
a O +
1-week O +
washout O +
period O +
with O +
a O +
controlled O +
diet O +
and O +
sunflower O +
oil O +
as O +
the O +
only O +
source O +
of O +
fat O +
was O +
followed O -
. O +

During O +
the O +
3 O +
days O +
before O +
and O +
on O +
the O +
intervention O +
day O -
, O +
a O +
very O +
low O -
- O -
phenolic O +
compound O +
diet O +
was O +
followed O -
. O +

At O +
baseline O +
( O -
0 O +
h O -
) O +
and O +
at O +
post O -
- O -
ingestion O +
( O -
6 O +
h O -
) O -
, O +
total O +
RNA O +
was O +
isolated O +
and O +
gene O +
expression O +
( O -
29,082 O +
genes O -
) O +
was O +
evaluated O +
by O +
microarray O -
. O +

From O +
microarray O +
data O -
, O +
nutrient O -
- O -
gene O +
interactions O +
were O +
observed O +
in O +
genes O +
related O +
to O +
metabolism O -
, O +
cellular O +
processes O -
, O +
cancer B-Disease -
, O +
and O +
atherosclerosis B-Disease +
( O -
e.g. O +
USP48 O +
by O +
2.16 O -
; O +
OGT O +
by O +
1.68-fold O +
change O -
) O +
and O +
associated O +
processes O +
such O +
as O +
inflammation B-Disease +
( O -
e.g. O +
AKAP13 O +
by O +
2.30 O -
; O +
IL-10 O +
by O +
1.66-fold O +
change O -
) O +
and O +
DNA B-Disease +
damage I-Disease +
( O -
e.g. O +
DCLRE1C O +
by O +
1.47 O -
; O +
POLK O +
by O +
1.44- O +
fold O +
change O -
) O -
. O +

When O +
results O +
obtained O +
by O +
microarray O +
were O +
verified O +
by O +
qRT O -
- O -
PCR O +
in O +
nine O +
genes O -
, O +
full O +
concordance O +
was O +
achieved O +
only O +
in O +
the O +
case O +
of O +
up O -
- O -
regulated O +
genes O -
. O +

Changes O +
were O +
observed O +
at O +
a O +
real O -
- O -
life O +
dose O +
of O +
olive O +
oil O -
, O +
as O +
it O +
is O +
daily O +
consumed O +
in O +
some O +
Mediterranean O +
areas O -
. O +

Our O +
results O +
support O +
the O +
hypothesis O +
that O +
postprandial O +
protective O +
changes O +
related O +
to O +
olive O +
oil O +
consumption O +
could O +
be O +
mediated O +
through O +
gene O +
expression O +
changes O -
. O +

Higher O +
coffee O +
consumption O +
has O +
been O +
associated O +
inversely O +
with O +
the O +
incidence O +
of O +
chronic B-Disease +
liver I-Disease +
disease I-Disease +
in O +
population O +
studies O -
. O +

We O +
examined O +
the O +
relationship O +
of O +
coffee O +
consumption O +
with O +
liver B-Disease +
disease I-Disease +
progression O +
in O +
individuals O +
with O +
advanced B-Disease +
hepatitis I-Disease +
C I-Disease -
- I-Disease -
related I-Disease +
liver I-Disease +
disease I-Disease -
. O +

Baseline O +
coffee O +
and O +
tea O +
intake O +
were O +
assessed O +
in O +
766 O +
participants O +
of O +
the O +
Hepatitis O +
C O +
Antiviral O +
Long O -
- O -
Term O +
Treatment O +
against O +
Cirrhosis B-Disease +
( O -
HALT O -
- O -
C O -
) O +
trial O +
who O +
had O +
hepatitis O +
C O -
- O -
related O +
bridging O +
fibrosis B-Disease +
or O +
cirrhosis B-Disease +
on O +
liver O +
biopsy O +
and O +
failed O +
to O +
achieve O +
a O +
sustained O +
virological O +
response O +
to O +
peginterferon O +
plus O +
ribavirin O +
treatment O -
. O +

Participants O +
were O +
followed O +
for O +
3.8 O +
years O +
for O +
clinical O +
outcomes O +
and O -
, O +
for O +
those O +
without O +
cirrhosis B-Disease -
, O +
a O +
2-point O +
increase O +
in O +
Ishak O +
fibrosis B-Disease +
score O +
on O +
protocol O +
biopsies O -
. O +

At O +
baseline O -
, O +
higher O +
coffee O +
consumption O +
was O +
associated O +
with O +
less O +
severe O +
steatosis O +
on O +
biopsy O -
, O +
lower O +
serum O +
aspartate O +
aminotransferase O +
( O -
AST O -
) O -
/ O -
alanine O +
aminotransferase O +
( O -
ALT O -
) O +
ratio O -
, O +
alpha O -
- O -
fetoprotein O -
, O +
insulin O -
, O +
and O +
homeostatic O +
model O +
assessment O +
( O -
HOMA2 O -
) O +
score O -
, O +
and O +
higher O +
albumin O +
( O -
P O +
< O +
0.05 O +
for O +
all O -
) O -
. O +

Two O +
hundred O +
thirty O +
patients O +
had O +
outcomes O -
. O +

Outcome O +
rates O +
declined O +
with O +
increasing O +
coffee O +
intake O -
: O +
11.1 O -
/ O -
100 O +
person O -
- O -
years O +
for O +
none O -
, O +
12.1 O +
for O +
less O +
than O +
1 O +
cup O -
/ O -
day O -
, O +
8.2 O +
for O +
1 O +
to O +
fewer O +
than O +
3 O +
cups O -
/ O -
day O -
, O +
and O +
6.3 O +
for O +
3 O +
or O +
more O +
cups O -
/ O -
day O +
( O -
P O -
- O -
trend O +
= O +
0.0011 O -
) O -
. O +

Relative O +
risks O +
( O -
95 O -
% O +
confidence O +
intervals O -
) O +
were O +
1.11 O +
( O -
0.76 O -
- O -
1.61 O -
) O +
for O +
less O +
than O +
1 O +
cup O -
/ O -
day O -
; O +
0.70 O +
( O -
0.48 O -
- O -
1.02 O -
) O +
for O +
1 O +
to O +
fewer O +
than O +
3 O +
cups O -
/ O -
day O -
; O +
and O +
0.47 O +
( O -
0.27 O -
- O -
0.85 O -
) O +
for O +
3 O +
or O +
more O +
cups O -
/ O -
day O +
( O -
P O -
- O -
trend O +
= O +
0.0003 O -
) O +
versus O +
not O +
drinking O -
. O +

Risk O +
estimates O +
did O +
not O +
vary O +
by O +
treatment O +
assignment O +
or O +
cirrhosis B-Disease +
status O +
at O +
baseline O -
. O +

Tea O +
intake O +
was O +
not O +
associated O +
with O +
outcomes O -
. O +

CONCLUSION O -
: O +
In O +
a O +
large O +
prospective O +
study O +
of O +
participants O +
with O +
advanced B-Disease +
hepatitis I-Disease +
C I-Disease -
- I-Disease -
related I-Disease +
liver I-Disease +
disease I-Disease -
, O +
regular O +
coffee O +
consumption O +
was O +
associated O +
with O +
lower O +
rates O +
of O +
disease O +
progression O -
. O +

Epidemiologic O +
studies O +
have O +
increasingly O +
suggested O +
that O +
caffeine O -
/ O -
coffee O +
could O +
be O +
an O +
effective O +
therapeutic O +
against O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
. O +

We O +
have O +
utilized O +
a O +
transgenic O +
mouse O +
model O +
for O +
AD B-Disease +
in O +
well O -
- O -
controlled O +
studies O +
to O +
determine O +
if O +
caffeine O +
and/or O +
coffee O +
have O +
beneficial O +
actions O +
to O +
protect O +
against O +
or O +
reverse O +
AD B-Disease -
- I-Disease -
like I-Disease +
cognitive I-Disease +
impairment I-Disease +
and O +
AD B-Disease +
pathology O -
. O +

AD B-Disease +
mice O +
given O +
caffeine O +
in O +
their O +
drinking O +
water O +
from O +
young O +
adulthood O +
into O +
older O +
age O +
showed O +
protection O +
against O +
memory B-Disease +
impairment I-Disease +
and O +
lower O +
brain O +
levels O +
of O +
the O +
abnormal O +
protein O +
( O -
amyloid O -
- O -
beta O -
; O +
Abeta O -
) O +
thought O +
to O +
be O +
central O +
to O +
AD B-Disease +
pathogenesis O -
. O +

Moreover O -
, O +
" O -
aged O -
" O +
cognitively O -
- O -
impaired O +
AD B-Disease +
mice O +
exhibited O +
memory O +
restoration O +
and O +
lower O +
brain O +
Abeta O +
levels O +
following O +
only O +
1 O -
- O -
2 O +
months O +
of O +
caffeine O +
treatment O -
. O +

We O +
believe O +
that O +
the O +
cognitive O +
benefits O +
of O +
chronic O +
caffeine O +
administration O +
in O +
AD B-Disease +
mice O +
are O +
due O +
to O +
caffeine O +
itself O -
, O +
and O +
not O +
metabolites O +
of O +
caffeine O -
; O +
this O -
, O +
because O +
our O +
long O -
- O -
term O +
administration O +
of O +
theophylline O +
to O +
AD B-Disease +
mice O +
provided O +
no O +
cognitive O +
benefits O -
. O +

In O +
acute O +
studies O +
involving O +
AD B-Disease +
mice O -
, O +
one O +
oral O +
caffeine O +
treatment O +
quickly O +
reduced O +
both O +
brain O +
and O +
plasma O +
Abeta O +
levels O +
- O +
similarly O +
rapid O +
alterations O +
in O +
plasma O +
Abeta O +
levels O +
were O +
seen O +
in O +
humans O +
following O +
acute O +
caffeine O +
administration O -
. O +
" O +

Caffeinated O -
" O +
coffee O +
provided O +
to O +
AD B-Disease +
mice O +
also O +
quickly O +
decreased O +
plasma O +
Abeta O +
levels O -
, O +
but O +
not O +
" O -
decaffeinated O -
" O +
coffee O -
, O +
suggesting O +
that O +
caffeine O +
is O +
critical O +
to O +
decreasing O +
blood O +
Abeta O +
levels O -
. O +

Caffeine O +
appears O +
to O +
provide O +
its O +
disease O -
- O -
modifying O +
effects O +
through O +
multiple O +
mechanisms O -
, O +
including O +
a O +
direct O +
reduction O +
of O +
Abeta O +
production O +
through O +
suppression O +
of O +
both O +
beta- O +
and O +
gamma O -
- O -
secretase O +
levels O -
. O +

These O +
results O +
indicate O +
a O +
surprising O +
ability O +
of O +
moderate O +
caffeine O +
intake O +
( O -
the O +
human O +
equivalent O +
of O +
500 O +
mg O +
caffeine O +
or O +
5 O +
cups O +
of O +
coffee O +
per O +
day O -
) O +
to O +
protect O +
against O +
or O +
treat O +
AD B-Disease +
in O +
a O +
mouse O +
model O +
for O +
the O +
disease O +
and O +
a O +
therapeutic O +
potential O +
for O +
caffeine O +
against O +
AD B-Disease +
in O +
humans O -
. O +

BACKGROUND O -
: O +
In O +
previous O +
studies O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
Nigella O +
Sativa O +
( O -
NS O -
) O +
has O +
protective O +
effects O +
against O +
ischemia B-Disease +
reperfusion I-Disease +
injury I-Disease +
on O +
various O +
organs O -
. O +

However O -
, O +
its O +
protective O +
effects O +
on O +
intestinal O +
tissue O +
against O +
ischemia B-Disease +
reperfusion I-Disease +
injury I-Disease +
are O +
unclear O -
. O +

We O +
aimed O +
to O +
determine O +
whether O +
NS O +
prevents O +
intestinal B-Disease +
ischemia I-Disease -
- I-Disease -
reperfusion I-Disease +
injury I-Disease +
in O +
rats O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Thirty O +
rats O +
were O +
divided O +
into O +
three O +
groups O +
as O +
sham O +
( O -
group O +
1 O -
) O -
, O +
control O +
( O -
group O +
2 O -
) O -
, O +
and O +
NS O -
- O -
treatment O +
group O +
( O -
group O +
3 O -
) O -
. O +

All O +
rats O +
underwent O +
intestinal O +
ischemia B-Disease +
for O +
60 O +
min O +
followed O +
by O +
a O +
60-min O +
period O +
of O +
reperfusion O -
. O +

Rats O +
were O +
intraperitoneally O +
infused O +
only O +
0.9 O -
% O +
saline O +
solutions O +
in O +
group O +
2 O -
. O +

Rats O +
in O +
the O +
group O +
3 O +
received O +
NS O +
( O -
0,2 O +
mL O -
/ O -
kg O -
) O +
intraperitoneally O -
, O +
before O +
ischemia B-Disease +
and O +
before O +
reperfusion O -
. O +

Total O +
antioxidant O +
capacity O +
( O -
TAC O -
) O -
, O +
catalase O +
( O -
CAT O -
) O -
, O +
total O +
oxidative O +
status O +
( O -
TOS O -
) O -
, O +
oxidative O +
stress O +
index O +
( O -
OSI O -
) O -
, O +
and O +
myeloperoxidase O +
( O -
MPO O -
) O +
in O +
ileum O +
tissue O +
were O +
measured O -
. O +

Also O -
, O +
ileum O +
tissue O +
histopathology O +
was O +
evaluated O +
by O +
a O +
light O +
microscope O -
. O +

RESULTS O -
: O +
The O +
levels O +
of O +
liver O +
enzymes O +
in O +
group O +
3 O +
were O +
significantly O +
lower O +
than O +
those O +
in O +
group O +
2 O +
( O -
p O +
< O -
.01 O -
) O -
. O +

TAC O +
and O +
CAT O +
activity O +
levels O +
in O +
ileum O +
tissue O +
were O +
significantly O +
higher O +
in O +
group O +
3 O +
than O +
in O +
group O +
2 O -
. O +

TOS O -
, O +
OSI O -
, O +
and O +
MPO O +
in O +
ileum O +
tissue O +
were O +
significantly O +
lower O +
in O +
group O +
3 O +
than O +
group O +
2 O +
( O -
p O +
< O -
.05 O +
for O +
TOS O +
and O +
MPO O -
; O +
p O +
< O +
.01 O +
for O +
OSI O -
) O -
. O +

Histological O +
tissue O +
damage O +
was O +
milder O +
in O +
the O +
NS O +
treatment O +
group O +
than O +
in O +
the O +
control O +
group O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
suggest O +
that O +
NS O +
treatment O +
protected O +
the O +
rat O -
's O +
intestinal O +
tissue O +
against O +
intestinal B-Disease +
ischemia I-Disease -
- I-Disease -
reperfusion I-Disease +
injury I-Disease -
. O +

We O +
have O +
previously O +
reported O +
that O +
Eriobotrya O +
japonica O +
seed O +
extract O +
( O -
ESE O -
) O +
is O +
effective O +
for O +
the O +
treatment O +
of O +
various O +
gastric B-Disease +
mucosal I-Disease +
injuries I-Disease -
. O +

For O +
the O +
pharmaceutical O +
preparation O +
of O +
ESE O -
, O +
we O +
are O +
evaluating O +
deep O +
sea O +
water O +
( O -
DSW O -
) O -
, O +
which O +
contains O +
trace O +
elements O +
and O +
has O +
a O +
homeostasis O -
- O -
enhancing O +
effect O -
, O +
as O +
the O +
solvent O -
. O +

In O +
this O +
study O -
, O +
we O +
prepared O +
DSW O +
containing O +
ESE O +
( O -
ESE O +
+ O +
DSW O -
) O +
and O +
evaluated O +
its O +
usefulness O +
for O +
the O +
prevention O +
of O +
gastric B-Disease +
mucosal I-Disease +
injuries I-Disease +
using O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
- O -
induced O +
acute O +
gastric B-Disease +
mucosal I-Disease +
injury I-Disease +
models O +
in O +
male O +
Wistar O -
/ O -
ST O +
rats O -
. O +

Gastric B-Disease +
mucosal I-Disease +
injury I-Disease +
models O +
were O +
prepared O +
by O +
administering O +
indomethacin O +
at O +
30 O +
mg O -
/ O -
kg O +
orally O +
to O +
the O +
rats O +
after O +
a O +
24-h O +
fast O -
. O +

ESE O +
was O +
prepared O +
by O +
a O +
routine O +
procedure O +
and O +
administered O +
at O +
the O +
same O +
concentration O +
as O +
in O +
the O +
administration O +
to O +
humans O -
. O +

The O +
rats O +
were O +
divided O +
into O +
the O +
following O +
6 O +
groups O -
: O +
ESE O -
, O +
DSW O -
, O +
ESE O +
+ O +
DSW O -
, O +
tap O +
water O +
( O -
control O -
) O -
, O +
rebamipide O +
( O -
positive O +
control O -
) O -
, O +
or O +
untreated O -
. O +

Gastric B-Disease +
mucosal I-Disease +
injuries I-Disease +
were O +
evaluated O +
by O +
measuring O +
the O +
injury B-Disease +
area O -
, O +
lipid O +
peroxide O +
( O -
LPO O -
) O +
level O -
, O +
antioxidative O +
enzyme O +
level O -
, O +
and O +
volume O +
of O +
mucus O -
. O +

The O +
injury B-Disease +
area O +
and O +
LPO O +
levels O +
in O +
plasma O +
and O +
gastric O +
tissue O +
were O +
significantly O +
reduced O +
in O +
the O +
ESE O +
and O +
ESE O +
+ O +
DSW O +
groups O +
compared O +
with O +
the O +
control O +
and O +
DSW O +
group O -
. O +

The O +
plasma O +
and O +
gastric O +
tissue O +
antioxidative O +
enzyme O +
levels O +
were O +
significantly O +
higher O +
in O +
the O +
ESE O +
and O +
ESE O +
+ O +
DSW O +
groups O +
than O +
in O +
the O +
control O +
group O -
. O +

These O +
results O +
suggest O +
that O +
DSW O -
, O +
when O +
combined O +
with O +
ESE O -
, O +
inhibits O +
antioxidative O +
enzymes O -
, O +
and O +
enhances O +
the O +
gastric O +
mucosal O +
protecting O +
effect O +
of O +
ESE O -
. O +

Hibiscus O +
sabdariffa O +
Linne O +
is O +
a O +
traditional O +
Chinese O +
rose O +
tea O +
and O +
has O +
been O +
effectively O +
used O +
in O +
folk O +
medicines O +
for O +
treatment O +
of O +
hypertension B-Disease -
, O +
inflammatory B-Disease +
conditions I-Disease -
. O +

H. O +
sabdariffa O +
aqueous O +
extracts O +
( O -
HSE O -
) O +
were O +
prepared O +
from O +
the O +
dried O +
flowers O +
of O +
H. O +
sabdariffa O +
L. O -
, O +
which O +
are O +
rich O +
in O +
phenolic O +
acids O -
, O +
flavonoids O +
and O +
anthocyanins O -
. O +

In O +
this O +
review O -
, O +
we O +
discuss O +
the O +
chemopreventive O +
properties O +
and O +
possible O +
mechanisms O +
of O +
various O +
H. O +
sabdariffa O +
extracts O -
. O +

It O +
has O +
been O +
demonstrated O +
that O +
HSE O -
, O +
H. O +
sabdariffa O +
polyphenol O -
- O -
rich O +
extracts O +
( O -
HPE O -
) O -
, O +
H. O +
sabdariffa O +
anthocyanins O +
( O -
HAs O -
) O -
, O +
and O +
H. O +
sabdariffa O +
protocatechuic O +
acid O +
( O -
PCA O -
) O +
exert O +
many O +
biologic O +
effects O -
. O +

PCA O +
and O +
HAs O +
protected O +
against O +
oxidative B-Disease +
damage I-Disease +
induced O +
by O +
tert O -
- O -
butyl O +
droperoxide O +
( O -
t O -
- O -
BHP O -
) O +
in O +
rat O +
primary O +
hepatocytes O -
. O +

In O +
rabbits O +
fed O +
cholesterol O +
and O +
human O +
experimental O +
studies O -
, O +
these O +
studies O +
imply O +
HSE O +
could O +
be O +
pursued O +
as O +
atherosclerosis B-Disease +
chemopreventive O +
agents O +
as O +
they O +
inhibit O +
LDL O +
oxidation O -
, O +
foam O +
cell O +
formation O -
, O +
as O +
well O +
as O +
smooth O +
muscle O +
cell O +
migration O +
and O +
proliferation O -
. O +

The O +
extracts O +
also O +
offer O +
hepatoprotection O +
by O +
influencing O +
the O +
levels O +
of O +
lipid O +
peroxidation O +
products O +
and O +
liver O +
marker O +
enzymes O +
in O +
experimental O +
hyperammonemia B-Disease -
. O +

PCA O +
has O +
also O +
been O +
shown O +
to O +
inhibit O +
the O +
carcinogenic O +
action O +
of O +
various O +
chemicals O +
in O +
different O +
tissues O +
of O +
the O +
rat O -
. O +

HAs O +
and O +
HPE O +
were O +
demonstrated O +
to O +
cause O +
cancer B-Disease +
cell O +
apoptosis O -
, O +
especially O +
in O +
leukemia B-Disease +
and O +
gastric B-Disease +
cancer I-Disease -
. O +

More O +
recent O +
studies O +
investigated O +
the O +
protective O +
effect O +
of O +
HSE O +
and O +
HPE O +
in O +
streptozotocin O +
induced O +
diabetic B-Disease +
nephropathy I-Disease -
. O +

From O +
all O +
these O +
studies O -
, O +
it O +
is O +
clear O +
that O +
various O +
H. O +
sabdariffa O +
extracts O +
exhibit O +
activities O +
against O +
atherosclerosis B-Disease -
, O +
liver B-Disease +
disease I-Disease -
, O +
cancer B-Disease -
, O +
diabetes B-Disease +
and O +
other O +
metabolic B-Disease +
syndromes I-Disease -
. O +

These O +
results O +
indicate O +
that O +
naturally O +
occurring O +
agents O +
such O +
as O +
the O +
bioactive O +
compounds O +
in O +
H. O +
sabdariffa O +
could O +
be O +
developed O +
as O +
potent O +
chemopreventive O +
agents O +
and O +
natural O +
healthy O +
foods O -
. O +

Oxyresveratrol O +
is O +
a O +
potent O +
antioxidant O +
and O +
free O -
- O -
radical O +
scavenger O +
found O +
in O +
mulberry O +
wood O +
( O -
Morus O +
alba O +
L. O -
) O +
with O +
demonstrated O +
protective O +
effects O +
against O +
cerebral B-Disease +
ischemia I-Disease -
. O +

We O +
analyzed O +
the O +
neuroprotective O +
ability O +
of O +
oxyresveratrol O +
using O +
an O +
in O +
vitro O +
model O +
of O +
stretch O -
- O -
induced O +
trauma B-Disease +
in O +
co O -
- O -
cultures O +
of O +
neurons O +
and O +
glia O -
, O +
or O +
by O +
exposing O +
cultures O +
to O +
high O +
levels O +
of O +
glutamate O -
. O +

Cultures O +
were O +
treated O +
with O +
25 O +
M O -
, O +
50 O +
M O +
or O +
100 O +
M O +
oxyresveratrol O +
at O +
the O +
time O +
of O +
injury O -
. O +

Trauma B-Disease +
produced O +
marked O +
neuronal O +
death O +
when O +
measured O +
24 O +
h O +
post O -
- O -
injury O -
, O +
and O +
oxyresveratrol O +
significantly O +
inhibited O +
this O +
death O -
. O +

Microscopic O +
examination O +
of O +
glia O +
suggested O +
signs O +
of O +
toxicity O +
in O +
cultures O +
treated O +
with O +
100 O +
M O +
oxyresveratrol O -
, O +
as O +
demonstrated O +
by O +
elevated O +
S-100B O +
protein O +
release O +
and O +
a O +
high O +
proportion O +
of O +
cells O +
with O +
condensed O +
nuclei O -
. O +

Cultures O +
exposed O +
to O +
glutamate O +
( O -
100 O +
M O -
) O +
for O +
24 O +
h O +
exhibited O +
~ O +
37 O -
% O +
neuronal B-Disease +
loss I-Disease -
, O +
which O +
was O +
not O +
inhibited O +
by O +
oxyresveratrol O -
. O +

These O +
results O +
show O +
that O +
the O +
two O +
pathologies O +
of O +
high O +
glutamate O +
exposure O +
and O +
trauma B-Disease +
are O +
differentially O +
affected O +
by O +
oxyresveratrol O +
treatment O +
in O +
vitro O -
. O +

Further O +
studies O +
using O +
oxyresveratrol O +
in O +
trauma B-Disease +
models O +
are O +
warranted O -
, O +
as O +
toxicity O +
to O +
glia O +
could O +
be O +
beneficial O +
by O +
inhibiting O +
reactive O +
gliosis B-Disease -
, O +
which O +
often O +
occurs O +
after O +
trauma B-Disease -
. O +

BACKGROUND O -
: O +
High O +
blood O +
pressure O +
is O +
an O +
important O +
risk O +
factor O +
for O +
cardiovascular B-Disease +
disease I-Disease +
attributing O +
to O +
about O +
50 O -
% O +
of O +
cardiovascular O +
events O +
worldwide O +
and O +
37 O -
% O +
of O +
cardiovascular O +
related O +
deaths O +
in O +
Western O +
populations O -
. O +

Epidemiological O +
studies O +
suggest O +
that O +
cocoa O +
rich O +
products O +
reduce O +
the O +
risk O +
of O +
cardiovascular B-Disease +
disease I-Disease -
. O +

Flavanols O +
found O +
in O +
cocoa O +
have O +
been O +
shown O +
to O +
increase O +
the O +
formation O +
of O +
endothelial O +
nitric O +
oxide O +
which O +
promotes O +
vasodilation O +
and O +
therefore O +
blood O +
pressure O +
reduction O -
. O +

Previous O +
meta O -
- O -
analyses O +
have O +
shown O +
that O +
cocoa O -
- O -
rich O +
foods O +
may O +
reduce O +
blood O +
pressure O -
. O +

Recently O +
additional O +
trials O +
had O +
conflicting O +
results O -
. O +

OBJECTIVES O -
: O +
To O +
determine O +
the O +
effect O +
of O +
flavanol O -
- O -
rich O +
chocolate O +
or O +
cocoa O +
products O +
on O +
blood O +
pressure O +
in O +
people O +
with O +
or O +
without O +
hypertension B-Disease -
. O +

SEARCH O +
METHODS O -
: O +
We O +
searched O +
the O +
following O +
electronic O +
databases O +
from O +
inception O +
to O +
November O +
2011 O -
: O +
Cochrane O +
Hypertension O +
Group O +
Specialised O +
Register O -
, O +
CENTRAL O -
, O +
MEDLINE O +
and O +
EMBASE O -
. O +

In O +
addition O +
we O +
searched O +
international O +
trial O +
registries O -
, O +
and O +
the O +
reference O +
lists O +
of O +
review O +
articles O +
and O +
included O +
trials O -
. O +

SELECTION O +
CRITERIA O -
: O +
Randomised O +
controlled O +
trials O +
( O -
RCT O -
) O +
investigating O +
the O +
effects O +
of O +
chocolate O +
or O +
cocoa O +
products O +
on O +
systolic O +
and O +
diastolic O +
blood O +
pressure O +
in O +
adults O +
for O +
a O +
minimum O +
of O +
two O +
weeks O +
duration O -
. O +

DATA O +
COLLECTION O +
AND O +
ANALYSIS O -
: O +
Two O +
authors O +
independently O +
extracted O +
data O +
and O +
assessed O +
the O +
risk O +
of O +
bias O +
in O +
each O +
trial O +
in O +
consultation O +
with O +
a O +
third O +
author O -
. O +

Random O +
effects O +
meta O -
- O -
analyses O +
on O +
all O +
studies O +
fitting O +
the O +
inclusion O +
criteria O +
were O +
conducted O +
using O +
Review O +
Manager O +
version O +
5.1 O +
and O +
Stata O +
version O +
12 O -
. O +

Heterogeneity O +
was O +
explored O +
by O +
subgroup O +
analyses O +
and O +
univariate O +
meta O -
- O -
regression O +
analysis O +
of O +
several O +
variables O +
including O +
dosage O +
of O +
flavanol O +
content O +
( O -
total O +
or O +
monomers O -
) O +
in O +
chocolate O +
or O +
cocoa O +
products O -
, O +
blinding O -
, O +
baseline O +
blood O +
pressure O -
, O +
theobromine O +
content O -
, O +
sugar O +
content O -
, O +
body O -
- O -
mass O -
- O -
index O +
( O -
BMI O -
) O -
, O +
duration O +
and O +
age O -
. O +

MAIN O +
RESULTS O -
: O +
Twenty O +
studies O +
met O +
the O +
inclusion O +
criteria O -
. O +

Meta O -
- O -
analyses O +
of O +
the O +
20 O +
studies O +
involving O +
856 O +
mainly O +
healthy O +
participants O +
revealed O +
a O +
statistically O +
significant O +
blood O +
pressure O +
reducing O +
effect O +
of O +
flavanol O -
- O -
rich O +
cocoa O +
products O +
compared O +
with O +
control O +
in O +
short O -
- O -
term O +
trials O +
of O +
2 O -
- O -
18 O +
weeks O +
duration O -
: O +
Mean O +
difference O +
SBP O +
( O -
95%CI O -
) O -
: O +
-2.77 O +
( O -
-4.72 O -
, O +
-0.82 O -
) O +
mm O +
Hg O -
, O +
p=0.005 O -
, O +
n=20 O -
; O +
mean O +
difference O +
DBP O +
( O -
95%CI O -
) O -
: O +
- O +
2.20 O +
( O -
-3.46 O -
, O +
-0.93 O -
) O +
mm O +
Hg O -
, O +
p=0.006 O -
, O +
n=19 O +
available O +
for O +
DBP.Trials O +
provided O +
participants O +
with O +
30 O -
- O -
1080 O +
mg O +
of O +
flavanols O +
( O -
mean=545.5 O +
mg O -
) O +
in O +
3.6 O -
- O -
105 O +
g O +
of O +
cocoa O +
products O +
per O +
day O +
in O +
the O +
active O +
intervention O +
group O -
. O +

In O +
half O +
of O +
the O +
trials O +
( O -
n=10 O -
) O +
the O +
active O +
group O +
consumed O +
500 O -
- O -
750 O +
mg O +
of O +
flavanols O +
per O +
day O -
. O +

The O +
control O +
group O +
received O +
either O +
a O +
flavanol O -
- O -
free O +
product O +
( O -
n=12 O -
) O +
or O +
a O +
low O -
- O -
flavanol O +
containing O +
cocoa O +
powder O +
( O -
6.4 O +
and O +
41 O +
mg O +
flavanols O -
, O +
n=8 O -
) O -
. O +

Subgroup O +
meta O -
- O -
analysis O +
of O +
trials O +
with O +
a O +
flavanol O -
- O -
free O +
control O +
group O +
revealed O +
a O +
significant O +
blood O +
pressure O +
reducing O +
effect O -
, O +
in O +
contrast O +
to O +
trials O +
using O +
a O +
low O -
- O -
flavanol O +
product O +
in O +
the O +
control O +
group O -
. O +

This O +
analysis O +
may O +
have O +
been O +
confounded O +
by O +
trial O +
duration O +
and O +
the O +
level O +
of O +
blinding O +
of O +
participants O -
. O +

Trial O +
duration O +
was O +
short O +
( O -
mean O +
4.4 O +
weeks O -
, O +
range O +
2 O -
- O -
8 O +
weeks O -
, O +
n=19 O -
, O +
and O +
one O +
trial O +
of O +
18 O +
weeks O -
) O -
. O +

A O +
significant O +
blood O +
pressure O +
reducing O +
effect O +
was O +
evident O +
in O +
trials O +
of O +
2 O +
weeks O +
duration O +
( O -
n=9 O -
) O -
, O +
but O +
not O +
in O +
trials O +
of O +
> O -
2 O +
weeks O +
duration O +
( O -
n=11 O -
) O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
seven O +
out O +
of O +
the O +
nine O +
trials O +
( O -
78 O -
% O -
) O +
of O +
2 O +
weeks O +
duration O +
also O +
had O +
a O +
flavanol O -
- O -
free O +
control O +
group O -
. O +

Therefore O -
, O +
subgroup O +
analysis O +
by O +
duration O +
might O +
be O +
confounded O +
by O +
flavanol O +
dosage O +
used O +
in O +
the O +
control O +
groups O -
, O +
and O +
the O +
level O +
of O +
blinding O +
of O +
participants O -
. O +

Adverse O +
effects O +
including O +
gastrointestinal O +
complaints O +
and O +
distaste O +
of O +
the O +
trial O +
product O +
were O +
reported O +
by O +
5 O -
% O +
of O +
patients O +
in O +
the O +
active O +
cocoa O +
intervention O +
group O +
and O +
1 O -
% O +
of O +
patients O +
in O +
the O +
control O +
groups O -
. O +

AUTHORS O -
' O +
CONCLUSIONS O -
: O +
Flavanol O -
- O -
rich O +
chocolate O +
and O +
cocoa O +
products O +
may O +
have O +
a O +
small O +
but O +
statistically O +
significant O +
effect O +
in O +
lowering O +
blood O +
pressure O +
by O +
2 O -
- O -
3 O +
mm O +
Hg O +
in O +
the O +
short O +
term O -
. O +

Our O +
findings O +
are O +
limited O +
by O +
the O +
heterogeneity O +
between O +
trials O -
, O +
which O +
was O +
explored O +
by O +
univariate O +
meta O -
- O -
regression O +
and O +
subgroup O +
analyses O -
. O +

Subgroup O +
meta O -
- O -
analysis O +
of O +
trials O +
using O +
a O +
flavanol O -
- O -
free O +
control O +
group O +
revealed O +
a O +
significant O +
blood O +
pressure O +
reducing O +
effect O +
of O +
cocoa O -
, O +
whereas O +
analysis O +
of O +
trials O +
using O +
a O +
low O -
- O -
flavanol O +
control O +
product O +
did O +
not O -
. O +

While O +
it O +
appears O +
that O +
shorter O +
trials O +
of O +
2 O +
weeks O +
duration O +
were O +
more O +
effective O -
, O +
analysis O +
may O +
be O +
confounded O +
by O +
type O +
of O +
control O +
and O +
unblinding O +
of O +
participants O -
, O +
as O +
the O +
majority O +
of O +
2-week O +
trials O +
also O +
used O +
a O +
flavanol O -
- O -
free O +
control O +
and O +
unblinding O +
of O +
participants O -
. O +

Results O +
of O +
these O +
and O +
other O +
subgroup O +
analyses O +
based O +
on O -
, O +
for O +
example O -
, O +
age O +
of O +
participants O -
, O +
should O +
be O +
interpreted O +
with O +
caution O +
and O +
need O +
to O +
be O +
confirmed O +
or O +
refuted O +
in O +
trials O +
using O +
direct O +
randomized O +
comparison O -
. O +

Long O -
- O -
term O +
trials O +
investigating O +
the O +
effect O +
of O +
cocoa O +
products O +
are O +
needed O +
to O +
determine O +
whether O +
or O +
not O +
blood O +
pressure O +
is O +
reduced O +
on O +
a O +
chronic O +
basis O +
by O +
daily O +
ingestion O +
of O +
cocoa O -
. O +

Furthermore O -
, O +
long O -
- O -
term O +
trials O +
investigating O +
the O +
effect O +
of O +
cocoa O +
on O +
clinical O +
outcomes O +
are O +
also O +
needed O +
to O +
assess O +
whether O +
cocoa O +
has O +
an O +
effect O +
on O +
cardiovascular O +
events O +
and O +
to O +
assess O +
potential O +
adverse O +
effects O +
associated O +
with O +
chronic O +
ingestion O +
of O +
cocoa O +
products O -
. O +

HYPOTHESIS O -
: O +
The O +
present O +
study O +
evaluates O +
the O +
hypothesis O +
that O +
sour O +
cherry O +
seed O +
extract O +
( O -
SCSE O -
) O +
protects O +
against O +
cardiovascular B-Disease +
disease I-Disease +
and O +
inflammation O +
in O +
hypercholesterolemic O +
rabbits O -
, O +
and O +
that O +
this O +
protection O +
correlates O +
with O +
SCSE O -
- O -
induced O +
activity O +
of O +
heme O +
oxygenase- O +
1 O +
( O -
HO-1 O -
) O -
, O +
a O +
cytoprotective O +
enzyme O +
contributing O +
to O +
oxidative O +
stress O +
responses O -
. O +

METHODS O -
: O +
18 O +
New O +
Zealand O +
white O +
rabbits O +
were O +
divided O +
into O +
three O +
groups O +
receiving O -
: O +
I. O +
cholesterol O -
- O -
free O +
rabbit O +
chow O -
; O +
II O -
. O +
chow O +
containing O +
2 O -
% O +
cholesterol O -
; O +
or O +
III O -
. O +

2 O -
% O +
cholesterol O +
plus O +
SCSE O +
for O +
16 O +
weeks O -
. O +

Heart O +
functions O +
were O +
monitored O +
by O +
echocardiography O +
0 O -
, O +
4 O -
, O +
and O +
16 O +
weeks O +
after O +
the O +
initiation O +
of O +
cholesterol O -
- O -
supplemented O +
feeding O -
. O +

At O +
the O +
16-week O +
time O -
- O -
point O -
, O +
isolated O +
hearts O +
were O +
subjected O +
to O +
ischemia O -
- O -
reperfusion O +
( O -
I O -
/ O -
R O -
) O -
, O +
followed O +
by O +
measurement O +
of O +
heart O +
rate O +
( O -
HR O -
) O -
, O +
aortic O +
flow O +
( O -
AF O -
) O -
, O +
coronary O +
flow O +
( O -
CF O -
) O -
, O +
aortic O +
pressure O +
( O -
AoP O -
) O -
, O +
and O +
left O +
ventricular O +
developed O +
pressure O +
( O -
LVDP O -
) O -
. O +

Myocardial O +
infarct O +
size O +
was O +
determined O +
using O +
triphenyl O +
tetrazolium O +
chloride O +
( O -
TTC O -
) O -
. O +

Quantification O +
of O +
fatty O +
streaks O +
was O +
assessed O +
using O +
Sudan O -
- O -
III O +
staining O -
. O +

Western O +
blot O +
analysis O +
was O +
used O +
to O +
determine O +
the O +
content O +
of O +
cytochrome O +
c O +
oxidase O +
III O +
( O -
COX O +
III O -
) O -
, O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
and O +
HO-1 O +
in O +
the O +
myocardium O -
. O +

RESULTS O -
: O +
Relative O +
to O +
cholesterol O -
- O -
treated O +
animals O +
not O +
receiving O +
SCSE O -
, O +
SCSE O -
- O -
treated O +
animals O +
exhibited O +
significantly O +
improved O +
cardiac O +
function O +
and O +
improved O +
peak O +
early O +
diastolic O +
velocity O +
to O +
peak O +
atrial O +
velocity O +
ratio O +
( O -
E' O -
/ O -
A O -
' O -
) O -
, O +
along O +
with O +
decreased O +
atherosclerotic O +
plaque O +
formation O +
and O +
infarct O +
size O -
. O +

Increased O +
HO-1 O +
and O +
COX O +
III O +
protein O +
expression O +
and O +
COX O +
activity O +
were O +
also O +
noted O +
in O +
hearts O +
from O +
SCSE O -
- O -
treated O +
rabbits O -
. O +

CONCLUSIONS O -
: O +
This O +
study O +
demonstrates O +
SCSE O +
cardioprotective O +
effects O +
on O +
hypercholesterolemic B-Disease +
hearts I-Disease -
. O +

Correlation O +
of O +
these O +
outcomes O +
with O +
HO-1 O +
expression O +
suggests O +
that O +
the O +
effect O +
may O +
be O +
mediated O +
by O +
activity O +
of O +
this O +
enzyme O -
. O +

However O -
, O +
definitive O +
proof O +
of O +
HO-1 O +
dependence O +
requires O +
further O +
investigation O -
. O +

Extract O +
of O +
Myrica O +
cerifera O +
bark O +
has O +
long O +
been O +
fruitfully O +
used O +
as O +
a O +
hepato O -
- O -
protective O +
and O +
anti B-Disease -
- I-Disease -
cancer I-Disease +
drug O +
in O +
various O +
complementary O +
and O +
alternative O +
systems O +
of O +
medicine O -
. O +

Myricanone O -
, O +
its O +
principal O +
bioactive O +
compound O -
, O +
had O +
also O +
been O +
reported O +
to O +
have O +
apoptosis O -
- O -
promoting O +
ability O -
. O +

We O +
evaluated O +
its O +
anti B-Disease -
- I-Disease -
cancer I-Disease +
potential O +
in O +
vitro O +
in O +
HepG2 O +
liver B-Disease +
cancer I-Disease +
cells O +
and O +
tried O +
to O +
understand O +
the O +
signal O +
cascades O +
involved O +
in O +
accomplishing O +
apoptosis O -
. O +

Further O -
, O +
we O +
ascertained O +
by O +
using O +
a O +
( O -
3- O -
( O -
4 O -
, O +
5-dimethylthiazol-2-yl O -
) O -
-2 O -
, O +
5-diphenyltetrazolium O +
bromide O +
assay O +
( O -
MTT O -
) O +
assay O +
if O +
it O +
had O +
cytotoxic O +
effects O +
on O +
normal O +
noncancerous O +
liver O +
cells O +
( O -
WRL-68 O -
) O -
. O +

We O +
deployed O +
various O +
tools O +
and O +
protocols O -
, O +
like O +
phase O +
contrast O -
, O +
scanning O +
electron O +
and O +
fluorescence O +
microscopies O -
, O +
performed O +
an O +
annexinV O -
- O -
FITC O -
/ O -
PI O +
assay O +
and O +
cell O +
cycle O +
analysis O -
, O +
and O +
estimated O +
the O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
generation O +
and O +
mitochondrial O +
membrane O +
depolarization O +
through O +
flow O +
cytometry O -
. O +

Further O -
, O +
analyses O +
of O +
cytochrome O -
- O -
c O +
translocation O +
and O +
of O +
HSP70 O +
and O +
caspase O +
expressions O +
were O +
also O +
done O +
by O +
using O +
immunoblota O +
and O +
Enzyme O +
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O -
. O +

Results O +
revealed O +
that O +
myricanone O +
induced O +
apoptosis O +
in O +
HepG2 O +
cells O +
through O +
generation O +
of O +
ROS O -
, O +
depolarization O +
of O +
the O +
mitochondrial O +
membrane O -
, O +
early O +
release O +
of O +
cytochrome O -
- O -
c O -
, O +
down O -
- O -
regulation O +
of O +
HSP70 O +
and O +
activation O +
of O +
a O +
caspase O +
cascade O -
; O +
it O +
had O +
no O -
, O +
or O +
insignificant O -
, O +
cytotoxic O +
effects O +
in O +
WRL-68 O +
cells O +
in O +
vitro O +
and O +
in O +
mice O +
in O +
vivo O -
. O +

Thus O -
, O +
myricanone O +
has O +
great O +
potential O +
for O +
use O +
in O +
formulating O +
an O +
effective O +
drug O +
against O +
both O +
hepatotoxicity O +
and O +
hepatocellular B-Disease +
cancer I-Disease -
. O +

Effect O +
of O +
feeding O +
15 O +
mg% O +
capsaicin O +
diet O +
or O +
3 O -
% O +
freeze O +
dried O +
onion O +
powder O +
containing O +
diet O +
were O +
examined O +
in O +
albino O +
rats O +
rendered O +
diabetic B-Disease +
with O +
streptozotocin O +
injection O -
. O +

Diabetic B-Disease +
rats O +
maintained O +
on O +
onion O +
diet O +
for O +
8 O +
weeks O +
excreted O +
comparatively O +
less O +
amounts O +
of O +
albumin O -
, O +
urea O -
, O +
creatinine O +
and O +
inorganic O +
phosphorus O -
. O +

Dietary O +
onion O +
also O +
partially O +
reversed O +
the O +
abnormalities O +
in O +
plasma O +
albumin O -
, O +
urea O -
, O +
creatinine O +
and O +
inorganic O +
phosphorus O +
in O +
diabetic B-Disease +
animals O -
. O +

Onion O +
also O +
produced O +
a O +
significant O +
reduction O +
in O +
hyperglycemic B-Disease +
status I-Disease +
of I-Disease +
diabetic I-Disease +
animals I-Disease -
. O +

Diabetic B-Disease +
rats O +
maintained O +
on O +
onion O +
diet O +
had O +
a O +
lowered O +
relative O +
liver O +
weight O +
at O +
the O +
end O +
of O +
the O +
study O +
compared O +
to O +
diabetic B-Disease +
control O +
group O -
. O +

Diabetic B-Disease +
rats O +
fed O +
onion O +
diet O +
also O +
exhibited O +
lowered O +
lipid O +
peroxides O +
in O +
circulation O +
and O +
in O +
urine O +
when O +
compared O +
to O +
diabetic B-Disease +
control O +
group O -
. O +

Blood O +
cholesterol O +
was O +
lowered O +
significantly O +
by O +
dietary O +
onion O +
in O +
diabetic B-Disease +
animals O -
. O +

Cholesterol O +
decrease O +
was O +
exclusively O +
from O +
LDL O -
- O -
VLDL O +
fraction O -
. O +

Significant O +
decrease O +
in O +
blood O +
phospholipids O +
and O +
triglycerides O +
also O +
brought O +
about O +
by O +
dietary O +
onion O -
. O +

Hepatic O +
cholesterol O -
, O +
triglycerides O -
, O +
phospholipids O +
which O +
were O +
elevated O +
under O +
diabetic B-Disease +
condition O +
were O +
countered O +
significantly O +
by O +
dietary O +
onion O -
. O +

Dietary O +
capsaicin O +
did O +
not O +
have O +
any O +
significant O +
influence O +
on O +
any O +
of O +
the O +
parameters O +
tested O +
in O +
diabetic B-Disease +
rats O -
. O +

Thus O -
, O +
the O +
study O +
reveals O +
that O +
onion O +
feeding O +
improves O +
the O +
metabolic O +
status O +
in O +
diabetic B-Disease +
condition O -
, O +
probably O +
because O +
of O +
its O +
hypoglycemic B-Disease +
as O +
well O +
as O +
hypocholesterolemic B-Disease +
effect I-Disease -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
the O +
effect O +
of O +
treatment O +
with O +
Ginkgo O +
biloba O +
extract O +
on O +
objective O +
measures O +
of O +
cognitive O +
function O +
in O +
patients O +
with O +
Alzheimer B-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O +
based O +
on O +
formal O +
review O +
of O +
the O +
current O +
literature O -
. O +

METHODS O -
: O +
An O +
attempt O +
was O +
made O +
to O +
identify O +
all O +
English O +
and O +
non O -
- O -
English O -
- O -
language O +
articles O +
in O +
which O +
G. O +
biloba O +
extract O +
was O +
given O +
to O +
subjects O +
with O +
dementia B-Disease +
or O +
cognitive B-Disease +
impairment I-Disease -
. O +

Inclusion O +
criteria O +
for O +
the O +
meta O -
- O -
analysis O +
were O +
( O -
1 O -
) O +
sufficiently O +
characterized O +
patients O +
such O +
that O +
it O +
was O +
clearly O +
stated O +
there O +
was O +
a O +
diagnosis O +
of O +
AD B-Disease +
by O +
either O +
Diagnostic O +
and O +
Statistical O +
Manual O +
of O +
Mental B-Disease +
Disorders I-Disease -
, O +
Revised O +
Third O +
Edition O -
, O +
or O +
National O +
Institute O +
of O +
Neurological B-Disease +
Disorders I-Disease +
and O +
Stroke B-Disease -
- I-Disease -
Alzheimer I-Disease -
's I-Disease +
Disease I-Disease +
and O +
Related O +
Disorders O +
Association O +
criteria O -
, O +
or O +
there O +
was O +
enough O +
clinical O +
detail O +
to O +
determine O +
this O +
by O +
our O +
review O -
; O +
( O -
2 O -
) O +
clearly O +
stated O +
study O +
exclusion O +
criteria O -
, O +
ie O -
, O +
those O +
studies O +
that O +
did O +
not O +
have O +
stated O +
exclusions O +
for O +
depression B-Disease -
, O +
other O +
neurologic B-Disease +
disease I-Disease -
, O +
and O +
central O +
nervous O +
system O -
- O -
active O +
medications O +
were O +
excluded O -
; O +
( O -
3 O -
) O +
use O +
of O +
standardized O +
ginkgo O +
extract O +
in O +
any O +
stated O +
dose O -
; O +
( O -
4 O -
) O +
randomized O -
, O +
placebo O -
- O -
controlled O +
and O +
double O -
- O -
blind O +
study O +
design O -
; O +
( O -
5 O -
) O +
at O +
least O +
1 O +
outcome O +
measure O +
was O +
an O +
objective O +
assessment O +
of O +
cognitive O +
function O -
; O +
and O +
( O -
6 O -
) O +
sufficient O +
statistical O +
information O +
to O +
allow O +
for O +
meta O -
- O -
analysis O -
. O +

RESULTS O -
: O +
Of O +
more O +
than O +
50 O +
articles O +
identified O -
, O +
the O +
overwhelming O +
majority O +
did O +
not O +
meet O +
inclusion O +
criteria O -
, O +
primarily O +
because O +
of O +
lack O +
of O +
clear O +
diagnoses O +
of O +
dementia B-Disease +
and O +
AD B-Disease -
. O +

Only O +
4 O +
studies O +
met O +
all O +
inclusion O +
criteria O -
. O +

In O +
total O +
there O +
were O +
212 O +
subjects O +
in O +
each O +
of O +
the O +
placebo O +
and O +
ginkgo O +
treatment O +
groups O -
. O +

Overall O +
there O +
was O +
a O +
significant O +
effect O +
size O +
of O +
0.40 O +
( O -
P<.0001 O -
) O -
. O +

This O +
modest O +
effect O +
size O +
translated O +
into O +
a O +
3 O -
% O +
difference O +
in O +
the O +
Alzheimer B-Disease +
Disease I-Disease +
Assessment O +
Scale O -
- O -
cognitive O +
subtest O -
. O +

CONCLUSIONS O -
: O +
Based O +
on O +
a O +
quantitative O +
analysis O +
of O +
the O +
literature O +
there O +
is O +
a O +
small O +
but O +
significant O +
effect O +
of O +
3- O +
to O +
6-month O +
treatment O +
with O +
120 O +
to O +
240 O +
mg O +
of O +
G. O +
biloba O +
extract O +
on O +
objective O +
measures O +
of O +
cognitive O +
function O +
in O +
AD B-Disease -
. O +

The O +
drug O +
has O +
not O +
had O +
significant O +
adverse O +
effects O +
in O +
formal O +
clinical O +
trials O +
but O +
there O +
are O +
2 O +
case O +
reports O +
of O +
bleeding O +
complications O -
. O +

In O +
AD B-Disease -
, O +
there O +
are O +
limited O +
and O +
inconsistent O +
data O +
that O +
preclude O +
determining O +
if O +
there O +
are O +
effects O +
on O +
noncognitive O +
behavioral O +
and O +
functional O +
measures O +
as O +
well O +
as O +
on O +
clinician O -
's O +
global O +
rating O +
scales O -
. O +

Further O +
research O +
in O +
the O +
area O +
will O +
need O +
to O +
determine O +
if O +
there O +
are O +
functional O +
improvements O +
and O +
to O +
determine O +
the O +
best O +
dosage O -
. O +

Additional O +
research O +
will O +
be O +
needed O +
to O +
define O +
which O +
ingredients O +
in O +
the O +
ginkgo O +
extract O +
are O +
producing O +
its O +
effect O +
in O +
individuals O +
with O +
AD B-Disease -
. O +

